Amgen's experimental Sjogren's drug meets late-stage trial goal
AMGN•Amgen said its experimental drug showed sustained reduction in disease activity in a late-stage study of patients with Sjogren's disease.
AMGN•AMGN•AMGN•Amgen said its experimental drug showed sustained reduction in disease activity in a late-stage study of patients with Sjogren's disease.
Amgen said its experimental drug showed sustained reduction in disease activity in a late-stage study of patients with Sjogren's disease, an autoimmune condition.
